When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...